Key result
Pre-reperfusion gamma-glutamylcysteine ethyl ester cuts infarct size by ~53% vs control.
Why the study?
Reduced glutathione protects cells against damage from reactive oxygen species during myocardial ischemia and reperfusion, but the infarct-limiting effects of gamma-glutamylcysteine ethyl ester were not examined in a canine model.
Does gamma-glutamylcysteine ethyl ester reduce infarct size in a canine model of myocardial ischemia and reperfusion?
Does gamma-glutamylcysteine ethyl ester reduce infarct size in a canine model of myocardial ischemia and reperfusion?
Answers are grounded in this paper and cite their sources.
Gamma-glutamylcysteine ethyl ester, a precursor of glutathione, significantly attenuates myocardial ischemia and reperfusion injury in a canine model when administered immediately before reperfusion.
OBJECTIVES: The aim of this study was to examine the infarct-limiting effects of gamma-glutamylcysteine ethyl ester, a newly discovered synthetic precursor of glutathione biosynthesis, in a canine model of myocardial infarction. BACKGROUND: Reduced glutathione plays an important role in protecting cells against damage induced by reactive oxygen species during myocardial ischemia and reperfusion. Gamma-glutamylcysteine ethyl ester is capable of penetrating into cells in its intact form and increasing intracellular glutathione levels. METHODS: Dogs were subjected to a 90-min coronary occlusion followed by 5 h of reperfusion. An intravenous bolus injection of gamma-glutamylcysteine ethyl ester (3 or 10 mg/kg body weight) was administered immediately before reperfusion. Regional myocardial blood flow was measured with the use of colored microspheres. RESULTS: Gamma-glutamylcysteine ethyl ester effectively reduced infarct size in a dose-dependent manner (mean +/- SEM 26.4 +/- 3.5% in the low dose group [3 mg/kg, n = 10] and 19.0 +/- 3.4% in the high dose group [10 mg/kg, n = 10]; each p < 0.05 vs. the value in the control group [40.6 +/- 4.8%, n = 10]). There were no differences between the control and treated groups in hemodynamic variables or regional myocardial blood flow either during the ischemic period or after reperfusion. The reduced glutathione content of ischemic myocardium in the control group (0.62 +/- 0.11 mumol/g, p < 0.01) was significantly lower than that in nonischemic myocardium (1.46 +/- 0.07 mumol/g), and it was preserved by treatment in a dose-dependent manner (3 mg/kg, 0.83 +/- 0.06 mumol/g; 10 mg/kg, 0.92 +/- 0.14 mumol/g; each p < 0.05 vs. control level). There were no differences in oxidized glutathione content between nonischemic and ischemic myocardium or among the three groups. CONCLUSIONS: Gamma-glutamylcysteine ethyl ester, a precursor of glutathione, significantly attenuates myocardial ischemia and reperfusion injury when administered immediately before reperfusion.
No takes yet. Share an insight, caveat, or question.
Hoshida et al. (1994) studied Myocardial infarction (n=30). Gamma-glutamylcysteine ethyl ester vs. Control group was evaluated on Infarct size (p=<0.05). Gamma-glutamylcysteine ethyl ester administered before reperfusion reduced infarct size in a dose-dependent manner (19.0% in 10 mg/kg group vs 40.6% in control, p<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: